Advanced in Immune Thrombocytopenic Purpura (ITP)

Dr. Kathleen W. Phelan

Hematology | Oncology
2160 S 1st Ave, Cardinal Bernardin Cancer Center, 
Maywood, IL 
Clinical Trials:Currently Recruiting for 3 Trials
Advanced in Immune Thrombocytopenic Purpura (ITP)
2160 S 1st Ave, Cardinal Bernardin Cancer Center, 
Maywood, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kathleen Phelan is a Hematologist and an Oncologist in Maywood, Illinois. Dr. Phelan is rated as an Advanced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her top areas of expertise are Multiple Myeloma, Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 5 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

2160 S 1st Ave, Cardinal Bernardin Cancer Center, Maywood, IL 60153

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Enrollment Status: Recruiting
Publish Date: October 10, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Mesna, Methotrexate, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate
Study Phase: Phase 3
A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
Enrollment Status: Recruiting
Publish Date: August 15, 2025
Intervention Type: Procedure, Drug
Study Drug: AKR1C3-Activated Prodrug OBI-3424
Study Phase: Phase 1/Phase 2
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
Enrollment Status: Completed
Publish Date: January 16, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Azacitidine, Cytarabine, Decitabine, Midostaurin, Nivolumab
Study Phase: Phase 2/Phase 3
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
View 5 Less Clinical Trials

5 Total Publications

Hearing Loss in a Patient with Waldenstrom Macroglobulinemia Receiving Bortezomib.
Hearing Loss in a Patient with Waldenstrom Macroglobulinemia Receiving Bortezomib.
Journal: Case reports in oncology
Published: August 11, 2023
Similar Doctors
Stanley Nabrinsky
Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. Stanley Nabrinsky
Hematology | Oncology
Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. Stanley Nabrinsky
Hematology | Oncology

Illinois Cancer Specialists

1710 N Randall Rd, 
Elgin, IL 
 (29.8 miles away)
847-931-0909
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stanley Nabrinsky is a Hematologist and an Oncologist in Elgin, Illinois. Dr. Nabrinsky is rated as a Distinguished provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, and Familial Colorectal Cancer.

Rajini Manjunath
Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. Rajini Manjunath
Hematology | Oncology
Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. Rajini Manjunath
Hematology | Oncology

Illinois Cancer Specialists

1710 N Randall Rd, 
Elgin, IL 
 (29.8 miles away)
847-931-0909
Languages Spoken:
English, Hindi, Kannada
See accepted insurances
Offers Telehealth

Rajini Manjunath is a Hematologist and an Oncologist in Elgin, Illinois. Dr. Manjunath is rated as a Distinguished provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Hemangioma Thrombocytopenia Syndrome, Immune Thrombocytopenic Purpura (ITP), and Bone Marrow Aspiration.

Syed A. Zahir
Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. Syed A. Zahir
Hematology | Oncology
Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. Syed A. Zahir
Hematology | Oncology

Illinois Cancer Specialists

1710 N Randall Rd, 
Elgin, IL 
 (29.8 miles away)
847-931-0909
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Syed Zahir is a Hematologist and an Oncologist in Elgin, Illinois. Dr. Zahir is rated as a Distinguished provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Pulmonary Embolism, Lung Cancer, Pleuropulmonary Blastoma, Polycythemia Vera, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Phelan's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 38 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile